JP2023539736A - 拮抗性ｃｄ４０モノクローナル抗体で自己免疫性疾患を処置する方法 - Google Patents

拮抗性ｃｄ４０モノクローナル抗体で自己免疫性疾患を処置する方法 Download PDF

Info

Publication number
JP2023539736A
JP2023539736A JP2023513407A JP2023513407A JP2023539736A JP 2023539736 A JP2023539736 A JP 2023539736A JP 2023513407 A JP2023513407 A JP 2023513407A JP 2023513407 A JP2023513407 A JP 2023513407A JP 2023539736 A JP2023539736 A JP 2023539736A
Authority
JP
Japan
Prior art keywords
antibody
antigen
dose
binding
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539736A5 (https=
JPWO2022046942A5 (https=
Inventor
イェ，イン
アラス，アービ
シャルダ，ニディ
ストラザーズ，メアリー
プライス，カレン
ギルギス，イハブ
フラ，アベラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2023539736A publication Critical patent/JP2023539736A/ja
Publication of JP2023539736A5 publication Critical patent/JP2023539736A5/ja
Publication of JPWO2022046942A5 publication Critical patent/JPWO2022046942A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2023513407A 2020-08-25 2021-08-25 拮抗性ｃｄ４０モノクローナル抗体で自己免疫性疾患を処置する方法 Pending JP2023539736A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070209P 2020-08-25 2020-08-25
US63/070,209 2020-08-25
PCT/US2021/047610 WO2022046942A1 (en) 2020-08-25 2021-08-25 Method of treating an autoimmune disease with antagonistic cd40 monoclonal antibodies

Publications (3)

Publication Number Publication Date
JP2023539736A true JP2023539736A (ja) 2023-09-19
JP2023539736A5 JP2023539736A5 (https=) 2024-07-23
JPWO2022046942A5 JPWO2022046942A5 (https=) 2024-07-23

Family

ID=77693641

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513407A Pending JP2023539736A (ja) 2020-08-25 2021-08-25 拮抗性ｃｄ４０モノクローナル抗体で自己免疫性疾患を処置する方法

Country Status (11)

Country Link
US (1) US20230331860A1 (https=)
EP (1) EP4204099A1 (https=)
JP (1) JP2023539736A (https=)
KR (1) KR20230054451A (https=)
CN (1) CN116322761A (https=)
AU (1) AU2021331087A1 (https=)
BR (1) BR112023002803A2 (https=)
CA (1) CA3190727A1 (https=)
IL (1) IL300765A (https=)
MX (1) MX2023002093A (https=)
WO (1) WO2022046942A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020106620A1 (en) * 2018-11-19 2020-05-28 Bristol-Myers Squibb Company Antagonistic cd40 monoclonal antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
TWI788340B (zh) * 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
AU2018361743A1 (en) * 2017-11-03 2020-04-09 Novartis Ag Anti-CD40 antibodies for use in treatment of Sjogren's syndrome

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020106620A1 (en) * 2018-11-19 2020-05-28 Bristol-Myers Squibb Company Antagonistic cd40 monoclonal antibodies and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LANCET RHEUMATOL., vol. 2, JPN6025032015, January 2020 (2020-01-01), pages 142 - 152, ISSN: 0005657231 *

Also Published As

Publication number Publication date
AU2021331087A1 (en) 2023-04-20
CN116322761A (zh) 2023-06-23
MX2023002093A (es) 2023-03-15
WO2022046942A1 (en) 2022-03-03
BR112023002803A2 (pt) 2023-03-14
IL300765A (en) 2023-04-01
CA3190727A1 (en) 2022-03-03
EP4204099A1 (en) 2023-07-05
US20230331860A1 (en) 2023-10-19
KR20230054451A (ko) 2023-04-24

Similar Documents

Publication Publication Date Title
KR102627246B1 (ko) 길항작용 cd40 모노클로날 항체 및 그의 용도
KR102713355B1 (ko) 길항작용 cd40 모노클로날 항체 및 그의 용도
KR102493282B1 (ko) Tim3에 대한 항체 및 그의 용도
JP6703520B2 (ja) Ｃｄ３イプシロンおよびｂｃｍａに対する二特異性抗体
KR101537840B1 (ko) 항-인간 ｃｄ52 면역글루불린
CN103038254B (zh) 拮抗性抗il-7受体抗体及方法
JP7355976B2 (ja) Ｃｄ７０と結合する抗体、その調製および使用
CN106061999B (zh) Il-21抗体
AU3369701A (en) Antibodies to human il-1beta
JP2019500862A (ja) Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
JP6825033B2 (ja) Ｂａｆｆ及びｂ７ｒｐ１に特異的なタンパク質及びその使用
CA2321165A1 (en) Antibodies against human cd40
CN106554417A (zh) 抗ox40抗体和使用其的方法
CN104507968A (zh) 人cd30配体抗原结合蛋白
US20230330257A1 (en) Development of drug therapeutic agent containing adaptor and use thereof
CN117843789A (zh) 治疗性抗cd40配体抗体
JP2026027375A (ja) Ｔ細胞アダプター治療剤の開発及び使用
JP2023532248A (ja) 免疫関連疾患のためのｔｉｇｉｔに対するヒトモノクローナル抗体
JP7278623B2 (ja) 抗ｃｄ２７抗体およびその使用
TW202317603A (zh) hIL-2變體、抗IL-2抗體或其抗原結合片段、抗體-細胞因子融合蛋白及其製備方法和用途
JP2023539736A (ja) 拮抗性ｃｄ４０モノクローナル抗体で自己免疫性疾患を処置する方法
TW202144425A (zh) 特異性抗原結合分子，其製備方法及醫藥用途
US12590155B2 (en) Molecules binding PD-L1 and uses thereof
HK40104821A (zh) 人cd30配体抗原结合蛋白
JPWO2022117045A5 (https=)

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240712

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260130